Transcription of 免疫グロブリン大量静注療法 - jsnt.gr.jp
1 CQ-1 2006 IVIG II IVIG IVIG C2 IVIG 2008 open-label phase II Prevention of Relapse with intravenous immunoglobulin (PRIVIG) study 1) 128 MS 200mg/kg IVIG 45 400mg/kg IVIG 42 41 3 4 IVIG MRI 48 3 MRI IVIG phase II IVIG II 2008 European Federation of neurological Societies EFNS IVIG MS 4) IVIG MS 1999 MS110 IVIG 200mg/kg MRI T2 2 5) IVIG 2006 phase II 2 1 2 125 MS 41 IVIG 200mg/kg 42 IVIG 400mg/kg 42 3 6)
2 MRI T2 T2 T1 black hole EDSS EDSS 9 hole peg test EDSS 200mg/kg IVIG T2 T2 IVIG 2011 II 3 IVIG 2010 CQ11-6 IVIG IVIG 2010 CQ-2 second line C1 MS IVIG MS open-label 2) 1g 5 400mg/kg/day 5 IVIG 23 1 1 IVIG 5 24 24 3 IVIG 23 18 78% III 12 MS 400mg/kg IVIG 5 5 MS 1000mg/day 3 3) MRI 3 IVIG EDSS IVIG IVIG MS III 2008 European Federation of neurological Societies EFNS IVIG MS 4)
3 IVIG 2010 IVIG 1) Fazekas F, Lublin FD, Li D, Freedman MS, et al. intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology. 2008; 71(4): 265-271. 2) Tselis A, Perumal J, Caon C, et al. treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin . Eur J Neurol. 2008; 15(11): 1163-1167. 3) Elovaara I, Kuusisto H, Wu X, et al. intravenous immunoglobulins are a therapeutic option in the treatment of multiple sclerosis relapse. Clin Neuropharmacol.
4 2011; 34(2): 84-89. 4) Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008; 15(9): 893-908. 5) 6) GGS-MS3 2011 3 30 PubMed 2008/01/01 2011/12/31 Multiple Sclerosis AND intravenous immunoglobulin or IVIG 94 2008/01/01 2011/12/31 AND or intravenous immunoglobulin or IVIG 9
